What Is a Military Hospital in China?
For much of the past decade, policymakers have become increasingly concerned about the relationship between China's civilian research institutions and the People's Liberation Army (PLA). Export controls have expanded, sanctions have grown more targeted, and multinational companies have devoted greater attention to supply chains, research partnerships, and institutional due diligence. Across these discussions, one question appears repeatedly: Which Chinese institutions should be considered military?
At first glance, the answer seems straightforward. Military institutions are those owned and operated by the military. Hospitals bearing the name of the People's Liberation Army or one of China's Theater Commands would naturally fall into that category. Civilian hospitals would not. It is a distinction that feels intuitive because it mirrors the way many Western countries organize military medicine.
However, classifying military institutions is much more complicated as we must agree what we meant by the term military institution in the first place.
That distinction may sound academic, but it has practical consequences. Governments rely on institutional definitions when implementing sanctions and export controls. Pharmaceutical companies use them when evaluating research partners. Investors use them when assessing geopolitical risk. Every one of those decisions begins with the assumption that military institutions can be identified with reasonable precision.
Focusing this framework on China's pharmaceutical, biotechnology, and clinical drug trial ecosystem quickly complicated what initially appeared to be a simple classification exercise. China's clinical research system is one of the largest in the world. Public registries contained nearly 40,000 individual clinical site names, many referring to the same institution under different English translations, abbreviated names, specialty clinics, affiliated campuses, or satellite hospitals. After consolidating those records, the investigation identified approximately 23,863 distinct hospitals, 13,872 active interventional drug and biological trials, and 901 active clinical trials led by U.S. sponsors operating in China exist according to US government records. Those figures transformed what appeared to be a straightforward counting exercise into an examination of one of the world's largest biomedical research ecosystems.
Within that ecosystem, a surprisingly simple question became increasingly difficult to answer. What exactly qualifies as a military hospital?
The Definition Problem
Most readers probably have a mental picture of what a military hospital looks like. In the United States, military hospitals are generally easy to identify. They operate within the Department of Defense, serve military personnel and their families, and exist inside a clearly defined chain of command. Their institutional identity is rarely ambiguous.
Applying that same framework to China initially seems reasonable. Hospitals operating under the PLA General Hospital system, the Army Medical University, the Air Force Medical University, and hospitals assigned to the PLA's Theater Commands plainly fit that description. They possess explicit military organizational structures, military leadership, and military medical missions. By any conventional definition, they are military hospitals.
The difficulty appears only after moving beyond those obvious cases. Military medical universities oversee affiliated teaching hospitals. Military researchers collaborate with and even direct civilian academic medical centers. Military research organizations maintain publicly documented partnerships with civilian hospitals. Rather than finding a single, clearly defined subset of military hospitals, the investigation uncovered several overlapping institutional layers that resist simple classification.
One institution illustrates the problem particularly well. The Academy of Military Medical Sciences (AMMS) is a military research organization that has been sanctioned by the United States for its role in China's Military-Civil Fusion strategy. Yet publicly available records repeatedly place AMMS alongside leading civilian medical institutions through joint research programs, innovation units, collaborative laboratories, and scientific publications. Among the most prominent examples is West China Hospital, one of China's premier civilian academic medical centers, where AMMS-linked Innovation Units and nationally designated biotherapy infrastructure operate alongside conventional civilian clinical programs. These collaborations do not, by themselves, establish military control over civilian hospitals. They do demonstrate, however, that institutional relationships often extend well beyond the categories implied by a hospital's name.
The relationship between the AMMS and key hospitals extend well beyond simple research collaboration and into direct control Senior scientist Wei Yuquan simultaneously serves as Director of the State Key Laboratory of Biotherapy at West China Hospital while also leading an AMMS Innovation Unit and serving as Chief Scientist for multiple nationally designated biotechnology programs. AMMS is not acting purely as a research partner but directing and controlling the activity of civilian medical centers.
Using a narrow definition focused on formal PLA institutions identifies approximately 112 military hospitals. Expanding the analysis to include military medical universities, military naming conventions, affiliated institutions, and related organizational indicators increases that universe to approximately 2,187 hospitals. Those figures are not competing estimates. They answer different analytical questions. The narrower definition identifies hospitals operating directly within formal PLA structures. The broader definition captures a much larger institutional landscape displaying explicit military characteristics.
Military Hospitals Are Civilian Hospitals
If defining military hospitals proved more complicated than expected, understanding what those hospitals actually do proved even more surprising.
Outside China, military hospitals are commonly associated with combat medicine, trauma surgery, rehabilitation, and the healthcare needs of military personnel. Those missions remain important in China. They are not, however, the whole story.
The hospitals identified as military institutions are active participants in many of the same research fields partnering not just with local civilian hospitals but with global pharmaceuticals. Current clinical trials include work involving oncology, cardiovascular disease, transplantation, infectious disease, immunology, gene therapy, engineered immune-cell therapies, precision diagnostics, and advanced molecular medicine. Several formally identifiable PLA institutions are participating in studies involving CAR-T therapies, stem-cell transplantation, post-transplant immune management, viral surveillance, and multi-omics analysis.
The breadth of that activity becomes even clearer when viewed across the entire dataset. The PLA General Hospital naming family alone accounts for well over one thousand mapped clinical trials, while the Army Medical University and Third Military Medical University family contributes hundreds more. Research spans breast cancer, hepatocellular carcinoma, pancreatic cancer, lymphoma, cardiovascular disease, Alzheimer's disease, hepatitis, sepsis, COVID-19, transplantation, genomics, and cell- and gene-therapy. These institutions are not confined to battlefield medicine. They are participating across many of the fastest-moving areas of contemporary biomedical science.
None of these therapeutic areas is inherently military. Military hospitals are not simply treating military patients. The People’s Liberation Army is being funded by global pharmaceutical companies. Chinese military hospitals have become almost indistinguishable from civilian hospitals and even direct or control significant parts of the civilian hospital activities.
AMMS provides another illustration. Although widely recognized as a military medical research organization, publicly documented collaborations connect AMMS investigators with civilian universities, hospitals, and biotechnology programs across China. Examining AMMS in isolation reveals a military institution. Examining the institutions with which it collaborates reveals a much broader research network.
Given the sanctions upon AMMS, they cannot participate in US or foreign registered clinical trials. To avoid this inconvenience, AMMS has deep agreements with civilian and other military hospitals where those hospitals will avoid scrutiny but pass the benefits on to AMMS to avoid sanctions.
When reviewing active interventional drug trials in Xinjiang, the initial results appeared straightforward. Public clinical trial registries identified no formal military hospitals participating directly as trial sites. Had the analysis stopped there, the conclusion would have been simple. Xinjiang appeared disconnected from China's identifiable military hospital research system.
Only after examining the multicenter trial networks themselves did a different picture emerge. Of the 225 active interventional drug trials identified in Xinjiang, 89 studies or nearly forty percent, were participating in nationwide multicenter studies that included at least one formal military hospital elsewhere in China. Going deeper clear evidence of deep cooperation between the local hospitals and China’s military and security emerged painting very different picture of the clinical trials sector in Xinjiang.
Hiding in Plain Sight
We began by asking which hospitals in China should be considered military hospitals. The evidence suggests that question alone is no longer sufficient.
China's military is not confined to a small network of isolated hospitals conducting research exclusively for military personnel. It participates across one of the world's largest biomedical research ecosystems. Military hospitals conduct advanced research in oncology, transplantation, infectious disease, immunology, precision medicine, and cell and gene therapy. Military physicians and scientists publish alongside civilian researchers. Military organizations collaborate with leading academic medical centers. Military leadership appears within institutions that many outside observers would instinctively classify as civilian.
The Academy of Military Medical Sciences illustrates the point. AMMS is not merely another research collaborator. It is a sanctioned military research organization whose personnel, Innovation Units, laboratories, and leadership positions appear throughout China's broader biomedical research system. The question is no longer whether military institutions conduct biomedical research. The more important question is how deeply those institutions participate in directing, shaping, and benefiting from China's civilian research infrastructure.
That distinction matters because many of the world's largest pharmaceutical companies increasingly rely upon Chinese hospitals to conduct clinical research. Those trials bring funding, scientific expertise, advanced therapeutics, and international partnerships into China's medical system. If military institutions occupy leadership roles within that same ecosystem, the financial and scientific benefits extend well beyond the individual hospitals appearing on a clinical trial registration form.
The Xinjiang analysis demonstrates why institutional labels alone are no longer enough. Looking only at the list of participating hospitals suggested there was little formal military involvement. Looking instead at the multicenter trial networks revealed extensive collaboration with hospitals operating within China's formal military medical system.
That observation extends well beyond Xinjiang. Throughout this investigation, military organizations repeatedly appeared not as isolated actors or tangential research partners but as participants and directors within broader scientific networks linking universities, civilian hospitals, military hospitals, research laboratories, and biotechnology programs.
The conventional distinction between "military" and "civilian" medicine in China is at best incomplete framework for understanding how China's biomedical research ecosystem actually operates but in reality obfuscates or ignores the control the Chinese military exercise over civilian hospitals and research activity.
The articles that follow will examine that ecosystem in much greater detail. They will trace the organizational relationships connecting military research organizations to civilian hospitals, examine the role of military leadership within ostensibly civilian institutions, explore how those relationships influence clinical research across China, and investigate why regions such as Xinjiang reveal patterns that are difficult to recognize when institutions are viewed in isolation.